206 related articles for article (PubMed ID: 28649601)
1. Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.
Hare DJ; Cardoso BR; Raven EP; Double KL; Finkelstein DI; Szymlek-Gay EA; Biggs BA
NPJ Parkinsons Dis; 2017; 3():1. PubMed ID: 28649601
[TBL] [Abstract][Full Text] [Related]
2. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
3. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
4. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
[TBL] [Abstract][Full Text] [Related]
5. Baicalin and deferoxamine alleviate iron accumulation in different brain regions of Parkinson's disease rats.
Xiong P; Chen X; Guo C; Zhang N; Ma B
Neural Regen Res; 2012 Sep; 7(27):2092-8. PubMed ID: 25558221
[TBL] [Abstract][Full Text] [Related]
6. Combined Application of Quantitative Susceptibility Mapping and Diffusion Kurtosis Imaging Techniques to Investigate the Effect of Iron Deposition on Microstructural Changes in the Brain in Parkinson's Disease.
Yang L; Cheng Y; Sun Y; Xuan Y; Niu J; Guan J; Rong Y; Jia Y; Zhuang Z; Yan G; Wu R
Front Aging Neurosci; 2022; 14():792778. PubMed ID: 35370619
[TBL] [Abstract][Full Text] [Related]
7. [Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB
Arkh Patol; 2022; 84(2):13-19. PubMed ID: 35417944
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
[TBL] [Abstract][Full Text] [Related]
9. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
10. Altered systemic iron metabolism in Parkinson's disease.
Logroscino G; Marder K; Graziano J; Freyer G; Slavkovich V; LoIacono N; Cote L; Mayeux R
Neurology; 1997 Sep; 49(3):714-7. PubMed ID: 9305329
[TBL] [Abstract][Full Text] [Related]
11. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
[TBL] [Abstract][Full Text] [Related]
12. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
13. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
14. Brain Iron Metabolism Dysfunction in Parkinson's Disease.
Jiang H; Wang J; Rogers J; Xie J
Mol Neurobiol; 2017 May; 54(4):3078-3101. PubMed ID: 27039308
[TBL] [Abstract][Full Text] [Related]
15. Analysis of neuronal iron deposits in Parkinson's disease brain tissue by synchrotron x-ray spectromicroscopy.
Brooks J; Everett J; Lermyte F; Tjendana Tjhin V; Sadler PJ; Telling N; Collingwood JF
J Trace Elem Med Biol; 2020 Dec; 62():126555. PubMed ID: 32526631
[TBL] [Abstract][Full Text] [Related]
16. Adaptive cellular response of the substantia nigra dopaminergic neurons upon age-dependent iron accumulation.
Kwon K; Cho H; Lee S; Cho EJ; Yu W; Kok CYL; Je HS; Kim JI; Cho HJ; Kwon T
Aging Cell; 2022 Sep; 21(9):e13694. PubMed ID: 35984750
[TBL] [Abstract][Full Text] [Related]
17. [Morphochemical changes in the substantia nigra cellular structures in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB; Kutukova KA
Arkh Patol; 2017; 79(5):3-9. PubMed ID: 29027522
[TBL] [Abstract][Full Text] [Related]
18. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
19. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
[TBL] [Abstract][Full Text] [Related]
20. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
